[go: up one dir, main page]

WO2008120472A1 - 高脂血症の予防及び／又は治療剤 - Google Patents

高脂血症の予防及び／又は治療剤 Download PDF

Info

Publication number
WO2008120472A1
WO2008120472A1 PCT/JP2008/000788 JP2008000788W WO2008120472A1 WO 2008120472 A1 WO2008120472 A1 WO 2008120472A1 JP 2008000788 W JP2008000788 W JP 2008000788W WO 2008120472 A1 WO2008120472 A1 WO 2008120472A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
prophylactic
hyperlipemia
disclosed
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/000788
Other languages
English (en)
French (fr)
Inventor
Toshiaki Takizawa
Noriyuki Inoue
Katsutoshi Miyosawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Priority to ES08720655T priority Critical patent/ES2380752T3/es
Priority to KR1020097018191A priority patent/KR101420319B1/ko
Priority to CA2680407A priority patent/CA2680407C/en
Priority to US12/593,356 priority patent/US8426455B2/en
Priority to AT08720655T priority patent/ATE549323T1/de
Priority to EP08720655A priority patent/EP2141155B1/en
Priority to JP2009507415A priority patent/JP5275975B2/ja
Priority to CN2008800033811A priority patent/CN101627021B/zh
Priority to HK10104519.2A priority patent/HK1138277B/xx
Publication of WO2008120472A1 publication Critical patent/WO2008120472A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)

Abstract

　本発明は、血中のコレステロール及びトリグリセリドを低下させる効果に優れた高脂血症治療剤を提供する。本発明は、下記の一般式（１）（式中、各記号は明細書中と同義を示す。）で表される化合物又はその塩と、スタチン類、特にピタバスタチン類とを組み合わせてなる高脂血症の予防及び／又は治療剤、肥満や糖尿病の予防及び／治療剤、並びにメタボリックシンドロームの予防及び／又は治療剤に関する。
PCT/JP2008/000788 2007-03-29 2008-03-28 高脂血症の予防及び／又は治療剤 Ceased WO2008120472A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES08720655T ES2380752T3 (es) 2007-03-29 2008-03-28 Agente profiláctico y/o terapéutico para hiperlipidemia
KR1020097018191A KR101420319B1 (ko) 2007-03-29 2008-03-28 고지혈증 예방 및/또는 치료제
CA2680407A CA2680407C (en) 2007-03-29 2008-03-28 Prophylactic and/or therapeutic agent for hyperlipidemia
US12/593,356 US8426455B2 (en) 2007-03-29 2008-03-28 Prophylactic and/or therapeutic agent for hyperlipidemia
AT08720655T ATE549323T1 (de) 2007-03-29 2008-03-28 Prophylaktisches und/oder therapeutisches mittel gegen hyperlipidemie
EP08720655A EP2141155B1 (en) 2007-03-29 2008-03-28 Prophylactic and/or therapeutic agent for hyperlipidemia
JP2009507415A JP5275975B2 (ja) 2007-03-29 2008-03-28 高脂血症の予防及び／又は治療剤
CN2008800033811A CN101627021B (zh) 2007-03-29 2008-03-28 高脂血症的预防和/或治疗剂
HK10104519.2A HK1138277B (en) 2007-03-29 2008-03-28 Prophylactic and/or therapeutic agent for hyperlipemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-087081 2007-03-29
JP2007087081 2007-03-29

Publications (1)

Publication Number Publication Date
WO2008120472A1 true WO2008120472A1 (ja) 2008-10-09

Family

ID=39808058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000788 Ceased WO2008120472A1 (ja) 2007-03-29 2008-03-28 高脂血症の予防及び／又は治療剤

Country Status (11)

Country Link
US (1) US8426455B2 (ja)
EP (2) EP2141155B1 (ja)
JP (1) JP5275975B2 (ja)
KR (1) KR101420319B1 (ja)
CN (1) CN101627021B (ja)
AT (1) ATE549323T1 (ja)
CA (1) CA2680407C (ja)
ES (1) ES2380752T3 (ja)
PT (1) PT2141155E (ja)
TW (1) TWI407955B (ja)
WO (1) WO2008120472A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011037223A1 (ja) * 2009-09-28 2011-03-31 興和株式会社 内臓脂肪重量の低下剤
WO2014050134A1 (ja) * 2012-09-27 2014-04-03 興和株式会社 脂質異常症治療剤
WO2015030033A1 (ja) * 2013-08-28 2015-03-05 興和株式会社 脂質異常症治療剤
JP2019011325A (ja) * 2017-06-30 2019-01-24 興和株式会社 医薬組成物
JPWO2019216313A1 (ja) * 2018-05-08 2021-05-13 国立大学法人 岡山大学 心血管疾患に有用な医薬

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102977085B (zh) * 2011-10-27 2015-07-29 四川大学 2-芳基-苯并[d]噁唑、2-芳基-苯并[d]噻唑衍生物及其制备方法和用途
RS61403B1 (sr) 2016-07-29 2021-02-26 Kowa Co Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom
WO2019004466A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬
US11419855B2 (en) 2017-06-30 2022-08-23 Kowa Company, Ltd. Pharmaceutical preparation
EP3727376A4 (en) * 2017-12-21 2021-07-21 Kowa Company, Ltd. METHOD OF TREATMENT OF HYPERTRIGLYCERIDEMIA
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
EP3903780A4 (en) * 2018-12-27 2023-01-18 Kowa Company, Ltd. MEDICAL DEVICE
KR102289381B1 (ko) 2020-03-17 2021-08-17 주식회사 대웅테라퓨틱스 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279866A (ja) 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
US6511985B1 (en) 1998-12-18 2003-01-28 Bayer Aktiengesellschaft Combination of cerivastatin and fibrates
WO2003013608A1 (en) 2001-08-07 2003-02-20 Galephar M/F ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR
DE10200138A1 (de) 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
WO2003088962A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
WO2005023777A1 (ja) 2003-09-03 2005-03-17 Kowa Co., Ltd. Ppar活性化化合物及びこれを含有する医薬組成物
WO2006090756A1 (ja) 2005-02-25 2006-08-31 Kyorin Pharmaceutical Co., Ltd. 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
WO2000061556A1 (en) 1999-04-09 2000-10-19 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
JP4901218B2 (ja) 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
PL1852426T3 (pl) * 2005-02-23 2014-04-30 Kowa Co Sposób wytwarzania optycznie czynnego związku aktywującego PPAR oraz związku pośredniego
TW200714280A (en) 2005-06-01 2007-04-16 Takeda Pharmaceuticals Co Novel method of treating hyperlipidemia

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279866A (ja) 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
US5856336A (en) 1987-08-20 1999-01-05 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
US6511985B1 (en) 1998-12-18 2003-01-28 Bayer Aktiengesellschaft Combination of cerivastatin and fibrates
WO2003013608A1 (en) 2001-08-07 2003-02-20 Galephar M/F ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR
DE10200138A1 (de) 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
WO2003088962A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
WO2005023777A1 (ja) 2003-09-03 2005-03-17 Kowa Co., Ltd. Ppar活性化化合物及びこれを含有する医薬組成物
WO2006090756A1 (ja) 2005-02-25 2006-08-31 Kyorin Pharmaceutical Co., Ltd. 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ATHEROSCLEROSIS, vol. 124, 1996, pages 103 - 117
ATHEROSCLEROSIS, vol. 29, 1978, pages 269 - 275
ATHEROSCLEROSIS, vol. 74, 1988, pages 15 - 21
BIOCHIM. BIOPHYS. ACTA, vol. 1254, 1995, pages 7 - 12
DIABETES CARE, vol. 25, 2002, pages 1198 - 1202
INOUE I. ET AL.: "Fibrate and Statin Synergistically Increase the Transcriptional Activities of PPARgamma/RXRalpha and Decrease the Transactivation of NFkappaB", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 290, no. 1, 2002, pages 131 - 139, XP002996645 *
J. CLIN. THERAP. MED., vol. 17, 2001, pages 857 - 883
J. LIPID. RES., vol. 39, 1998, pages 75 - 84
J. PHARMACOL. SCI., vol. 103, no. 1, 2007, pages 244P
JOHNSON T.E. ET AL.: "Statins and PPARgamma agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 208, no. 3, 2005, pages 210 - 221, XP003006969 *
TANAKA T. ET AL.: "Koshiketsusho Gappei 2-gata Tonyobyo Kanja ni Taisuru Fenofibrate no Chokiteki Yuyosei", PROGRESS IN MEDICINE, vol. 26, 2006, pages 1111 - 1116, XP008142108 *
TERAMOTO T.: "Koshiketsusho Chiryo ni Okeru Fibrate-kei Yakuzai no Ichizuke - Daikibo Rinsho Shiken o Furikaette -", THERAPEUTIC RESEARCH, vol. 27, no. 10, 2006, pages 1979 - 1986, XP008116832 *
USUI ET AL., LIPID RES., vol. 43, 2002, pages 805 - 814
YAMAZAKI H. ET AL.: "Shinki HMG-CoA Kangen Koso Sogaiyaku Pitavastatin (Livalo-jo) no Yakuri Oyobi Yakubutsu Dotaiteki Tokucho to Rinsho Koka", FOLIA PHARMACOLOGICA JAPONICA, vol. 123, 2004, pages 349 - 362, XP008116671 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5679458B2 (ja) * 2009-09-28 2015-03-04 興和株式会社 内臓脂肪重量の低下剤
WO2011037223A1 (ja) * 2009-09-28 2011-03-31 興和株式会社 内臓脂肪重量の低下剤
US10258609B2 (en) 2012-09-27 2019-04-16 Kowa Company, Ltd. Therapeutic agent for dyslipidemia
WO2014050134A1 (ja) * 2012-09-27 2014-04-03 興和株式会社 脂質異常症治療剤
JPWO2014050134A1 (ja) * 2012-09-27 2016-08-22 興和株式会社 脂質異常症治療剤
EA024873B1 (ru) * 2012-09-27 2016-10-31 Кова Компани, Лтд. Терапевтическое средство при дислипидемии
US9572798B2 (en) 2012-09-27 2017-02-21 Kowa Company, Ltd. Therapeutic agent for dyslipidemia
US11013722B2 (en) 2012-09-27 2021-05-25 Kowa Company, Ltd. Therapeutic agent for dyslipidemia
US9931321B2 (en) 2012-09-27 2018-04-03 Kowa Company, Ltd. Therapeutic agent for dyslipidemia
WO2015030033A1 (ja) * 2013-08-28 2015-03-05 興和株式会社 脂質異常症治療剤
JP2018197273A (ja) * 2013-08-28 2018-12-13 興和株式会社 脂質異常症治療剤
JPWO2015030033A1 (ja) * 2013-08-28 2017-03-02 興和株式会社 脂質異常症治療剤
JP2019011325A (ja) * 2017-06-30 2019-01-24 興和株式会社 医薬組成物
JPWO2019216313A1 (ja) * 2018-05-08 2021-05-13 国立大学法人 岡山大学 心血管疾患に有用な医薬
JP7356968B2 (ja) 2018-05-08 2023-10-05 国立大学法人 岡山大学 心血管疾患に有用な医薬

Also Published As

Publication number Publication date
US8426455B2 (en) 2013-04-23
EP2141155A4 (en) 2010-05-19
KR20090129994A (ko) 2009-12-17
ES2380752T3 (es) 2012-05-18
ATE549323T1 (de) 2012-03-15
EP2433932A1 (en) 2012-03-28
JP5275975B2 (ja) 2013-08-28
TWI407955B (zh) 2013-09-11
KR101420319B1 (ko) 2014-07-16
CN101627021B (zh) 2012-11-28
JPWO2008120472A1 (ja) 2010-07-15
EP2141155B1 (en) 2012-03-14
PT2141155E (pt) 2012-05-23
CA2680407A1 (en) 2008-10-09
CN101627021A (zh) 2010-01-13
US20100069433A1 (en) 2010-03-18
HK1138277A1 (en) 2010-08-20
CA2680407C (en) 2015-04-21
TW200838510A (en) 2008-10-01
EP2141155A1 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
WO2008120472A1 (ja) 高脂血症の予防及び／又は治療剤
WO2008102749A1 (ja) 複素環化合物
WO2009051244A1 (ja) 複素環化合物
WO2008093639A1 (ja) ピラゾール化合物
WO2007118185A3 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2007056771A3 (en) Compounds for the treatment of metabolic disorders
WO2006112549A8 (ja) 縮合複素環化合物
WO2002100341A3 (en) Compounds for the treatment of metabolic disorders
WO2008142859A1 (ja) 新規なスピロオキシインドール化合物及びこれを含有する医薬
WO2008136428A1 (ja) 含窒素５員複素環化合物
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
WO2008011453A3 (en) SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
WO2007100535A3 (en) Oxyntomodulin derivatives
WO2007125547A3 (en) Novel process for statins and its pharmaceutically acceptable salts thereof
WO2007104789A3 (en) Amylin derivatives
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2007127726A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2007109354A3 (en) Peptide-peptidase inhibitor conjugates and methods of using same
MY158982A (en) Heterocyclic compound
WO2007127688A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007145835A3 (en) Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
WO2008005651A3 (en) Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880003381.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720655

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1020097018191

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008720655

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2680407

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009507415

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12593356

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE